Categories
Change Password!
Reset Password!
Intravenuos golimumab can help alleviate
the deleterious effects of psoriatic arthritis (PsA) on
quality of life and productivity.
The outcomes of the GO-VIBRANT trial published in
Clinical Rheumatology confirmed that golimumab when used intravenously (IV)
resulted in timely and sustained improvements in health-related quality of life
(HRQoL) and efficiency from Week 8 through 12 months in PsA patients. This
study by Alexis Ogdie et al. also found HRQoL and productivity improvements
could be linked with improvements in disease activity and functional capability
of the patient.
In this study, a total of 241 patients
were given golimumab
IV 2 mg per kg at Weeks 0, 4, then each 8 weeks through Week 52 in the
Golinumab group. Whereas, placebo at Weeks 0, 4, then each 8 weeks, with
crossover golimumab IV 2 mg per kg at Weeks 24, 28, then each 8 weeks
throughout Week 52. Different parameters were used to assess HRQoL.
At week 8, greater variations in golimumab group was observed concerning different HRQoL paramters as compared to the placebo group, as shown in below table:
At week 52, similar change from the
starting was observed in both the groups. HRQoL and productivity were usually
linked with disease activity and functional capability, with sustained
relationship from Week 8 till Week 52.
Clinical Rheumatology
The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial
Alexis Ogdie et al.
Comments (0)